Meeting
2023 ASCO Annual Meeting
Targeting AMP kinase in melanoma: A phase I trial of phenformin with dabrafenib/trametinib.
Authors
Paul B. Chapman
Memorial Sloan Kettering Cancer Center, New York, NY
Paul B. Chapman , Mark Klang , Michael A. Postow , Alexander Noor Shoushtari , Ryan J. Sullivan , Jedd D. Wolchok , Phillip Wong , Margaret K. Callahan , Jonathan Zippin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Advanced/Metastatic Disease
Clinical Trial Registration Number
NCT03026517
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 9536)
DOI
10.1200/JCO.2023.41.16_suppl.9536
Abstract #
9536
Poster Bd #
299
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
Phase 1 study of MEDI4736, an anti-PD-L1 antibody, in combination with dabrafenib and trametinib or trametinib alone in patients with unresectable or metastatic melanoma.
First Author: Michael S. Gordon
Poster
2021 ASCO Annual Meeting
Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).
First Author: Natalie Jackson
Poster
2018 ASCO Annual Meeting
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).
First Author: Matthew Dankner
Poster
2017 ASCO Annual Meeting
SWOG S1221: A phase 1 dose escalation study co-targeting MAPK-dependent and MAPK-independent BRAF inhibitor resistance in BRAF mutant advanced solid tumors with dabrafenib, trametinib, and GSK2141795 (ClinicalTrials.gov NCT01902173).
First Author: Alain Patrick Algazi